Navigation Links
Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
Date:8/30/2011

organization, enthusiasm of Pearl's clinical investigators, and our overall commitment to capital efficiency while generating high quality clinical data. In the next few months, we look forward to presenting results from the remaining three studies in our ongoing Phase 2b program, which is funded by our 2010 Series C financing. We intend to meet with the FDA in the first half of 2012, in preparation for PT003 registrational studies targeted to start in late 2012."

About COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment. Pearl is developing inhaled combination products designed to optimize the treatment of COPD.

About Pearl Therapeutics

Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
3. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
4. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
5. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
6. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
7. Prime Therapeutics Drug Trend Insights Reports One of the Lowest Drug Spending Increases in the Industry
8. Precision Therapeutics Named on Inc. 500
9. 5000 2011 List and Recognized for Achievements in Personalized Medicine Industry
10. Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
11. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... October 17, 2014 ... http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced the addition ... North American Automated External Defibrillators (AED) ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report North American ... the market of devices based upon ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... -- Talyst, a market leader in pharmacy automation will be ... Nashville, TN. The company will be ... onsite, remote medication dispensing. Talyst,s InSite ... securely dispense medication onsite, on demand. Remote dispensing cuts ... the correct medication gets to the correct patient in ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
... Reportlinker.com announces that a new ... its catalogue: ... to 2017 - Multiple Sclerosis, Major ... Half the Market Value in 2010 ...
... events organiser UBM Live , a division of UBM ... event, CPhI South East Asia to cater to the pharmaceutical ... 12 May at the Jakarta International Expo in Indonesia. The ... is being introduced to offer a meeting place for pharmaceutical ...
Cached Medicine Technology:Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20CPhI Global Portfolio Expands into South East Asia 2
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... October 20, 2014 Having been working in ... good knowledge of customer needs. According to James, one of ... with dazzling sequins, or with high-low skirts that add beauty ... huge demand. Recently, LunaDress has unveiled its new selection of ... fact, the company’s brand new items are available in over ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... at Facility, PLANO, Texas, Dec. 7 The ... Dallas will have a safer environment,thanks to the Senior ... ViewPoint Bank is funding the program through,the Senior Housing ... in the nation,s senior housing facilities., "Crime against ...
... CHAPEL HILL, N.C., Dec. 7 A recent ... readiness for launch by a non-New,Product Introduction team ... launches. This study, "Ensuring a Successful New Product ... executives,with the knowledge and data to optimize their ...
... Free, accurate,information on many neurological disorders is ... the National Institute of Neurological,Disorders and Stroke ... Health,(NIH). The website is available at espanol.ninds.nih.gov., ... website includes publications on,stroke, dementia, Parkinson,s disease, ...
... role in liver treatment , FRIDAY, Dec. 7 (HealthDay ... alcoholics with cirrhosis of the liver, says an Italian ... . , The study included 84 alcohol-dependent patients with ... or a placebo (42 patients). Total alcohol abstinence and ...
... be passed on to nursing infants, rat study shows , , ... mechanism by which a chemical known as perchlorate can collect ... newborns. , Used since the 1940s to manufacture explosives and ... water and food supply, experts say. , And high concentrations ...
... 7 Transcept Pharmaceuticals,Inc. today announced that Glenn A. ... expert panel on "Drug Development in a,Changed Environment" at ... New York Hotel at Times Square on Thursday, December ... panel will be moderated by Ken Trbovich, Vice,President, Capital ...
Cached Medicine News:Health News:ViewPoint Bank Funds Senior Crimestoppers Program at Meadows Health and Rehab Center in Dallas 2Health News:Best Practice Database: Complimentary Excerpt of 'Ensuring a Successful New Product Launch Through Effective Processes and Authority Roles' 2Health News:Baclofen Aids Abstinence in Alcoholics With Cirrhosis 2Health News:Environmental Toxin Collects in Breast Milk 2Health News:Environmental Toxin Collects in Breast Milk 3Health News:Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference 2
Toothed grasping forcep....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Micro cup pituitary forceps, semi-malleable shafts....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: